Trial Profile

Study of the Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Radionuclide Therapy Prior to Radical Prostatectomy in Men With High-risk Localised Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms LuTectomy

Most Recent Events

08 Nov 2024 Planned End Date changed from 30 Dec 2023 to 30 Aug 2025.
01 Mar 2024 Results of investigate the dosimetry, safety, and efficacy of upfront [177Lu]Lu-PSMA-617, published in the European Urology
17 Aug 2023 Planned End Date changed from 30 Jun 2023 to 30 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com